{"id":11938,"date":"2025-11-21T10:55:56","date_gmt":"2025-11-21T09:55:56","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=11938"},"modified":"2026-03-12T15:14:09","modified_gmt":"2026-03-12T14:14:09","slug":"amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/","title":{"rendered":"AMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance"},"content":{"rendered":"\n

Organis\u00e9e \u00e0 l\u2019\u00e9chelon mondial, l\u2019\u00abAMR Awareness Week\u00bb a pour but de sensibiliser \u00e0 l\u2019antibior\u00e9sistance et de faire progresser les approches de solutions. Cette s\u00e9rie de blogs propose un aper\u00e7u du r\u00f4le de l\u2019industrie pharmaceutique dans la lutte contre l\u2019antibior\u00e9sistance. La troisi\u00e8me et derni\u00e8re partie de ce blog porte sur les succ\u00e8s de la lutte contre l\u2019antiobior\u00e9sistance. La d\u00e9couverte d\u2019une toute nouvelle classe d\u2019antibiotiques a permis aux scientifiques de Roche de contribuer \u00e0 r\u00e9duire dans le monde entier le nombre de d\u00e9c\u00e8s caus\u00e9s par les infections nosocomiales.<\/p>\n\n\n\n

Blog de Roche pour l\u2019AMR awareness week 2025<\/strong><\/h2>\n\n\n\n

Engagement de Roche dans la cr\u00e9ation et le d\u00e9veloppement de la recherche et le d\u00e9veloppement de nouveaux m\u00e9dicaments pour lutter contre les r\u00e9sistances<\/strong><\/strong><\/p>\n\n\n\n

L\u2019antibior\u00e9sistance ou r\u00e9sistance aux antibiotiques est un enjeu capital de s\u00e9curit\u00e9 sanitaire \u00e0 l\u2019\u00e9chelon mondial. En 2019, 5.5 millions de personnes au monde sont d\u00e9c\u00e9d\u00e9es de maladies li\u00e9es aux antibior\u00e9sistances, dont 1.27 million de d\u00e9c\u00e8s directement imputables \u00e0 une infection bact\u00e9rienne antibior\u00e9sistante, sans compter la tuberculose r\u00e9sistante aux m\u00e9dicaments, autre cause de d\u00e9c\u00e8s significative. En outre, le manque d\u2019antibiotiques efficaces menace la m\u00e9decine moderne telle que nous la connaissons actuellement. Sans ces m\u00e9dicaments vitaux, des traitements pr\u00e9ventifs et curatifs de base qui nous semblent aller de soi sont impossibles et les infections nosocomiales (infections contract\u00e9es \u00e0 l\u2019h\u00f4pital) peuvent se r\u00e9pandre.<\/p>\n\n\n\n

\n
<\/div>\n\n
\n
\n
\n
\n \"Placeholder\"\n <\/div>\n\n
\n
\n

\u00abL\u2019antibior\u00e9sistance touche tout le monde, mais pas \u00e0 \u00e9galit\u00e9.\u00bb<\/h2>\n \n

Michael Lobritz (Responsable du domaine Maladies infectieuses au Centre de recherche et d\u00e9veloppement de Roche (Pharma Research and Early Development, pRED))<\/p>\n \n

<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n \n\n\n\n\n

Par exemple, les patient-e-s atteint-e-s d\u2019un cancer sont particuli\u00e8rement sujet-te-s aux infections et, chez ces personnes, l\u2019antibior\u00e9sistance est la premi\u00e8re cause de d\u00e9c\u00e8s autre que le cancer.<\/p>\n\n\n\n

Vu ces enjeux, il reste fort \u00e0 faire. Mais d\u00e9velopper de nouvelles classes d\u2019antibiotiques est un d\u00e9fi de taille, tant du point de vue \u00e9conomique que scientifique. Scientifiquement parlant, les bact\u00e9ries sont un casse-t\u00eate: \u00abLes bact\u00e9ries sont des cr\u00e9atures extr\u00eamement complexes, prot\u00e9g\u00e9es par plusieurs membranes ext\u00e9rieures qui leur permettent de survivre dans des environnements hostiles\u00bb, explique Michael Lobritz. \u00abIl est difficile de passer \u00e0 travers ces membranes et nous ne comprenons pas bien pourquoi.\u00bb Depuis des dizaines d\u2019ann\u00e9es, les scientifiques s\u2019efforcent de d\u00e9velopper de nouvelles classes chimiques pour surmonter les r\u00e9sistances. Et lorsqu\u2019ils\/elles trouvent une nouvelle approche, ils\/elles sont souvent confront\u00e9-e-s \u00e0 un autre d\u00e9fi de taille: les fortes doses requises pour que le m\u00e9dicament soit efficace risquent de mettre la sant\u00e9 humaine en danger.<\/p>\n\n\n\n

Surmonter ces obstacles requiert un engagement durable dans la recherche d\u2019approches nouvelles et innovantes, ind\u00e9pendamment des \u00e9checs potentiels. C\u2019est cet engagement que Roche offre, non seulement \u00e0 une, mais deux \u00e9quipes scientifiques, l\u2019une au Centre de recherche et d\u00e9veloppement (pRED) \u00e0 B\u00e2le, Suisse, l\u2019autre au Centre de recherche et d\u00e9veloppement Genentech (gRED) \u00e0 South San Francisco, Californie, \u00c9tats-Unis, qui toutes deux ont actuellement de nouvelles classes d\u2019antibiotiques tr\u00e8s int\u00e9ressantes en cours de d\u00e9veloppement et de nouvelles approches de recherche pour compl\u00e9ter le pipeline d\u2019antibiotiques en d\u00e9veloppement.<\/p>\n\n\n\n

\n
<\/div>\n\n
\n
\n
\n
\n \"Placeholder\"\n <\/div>\n\n
\n
\n

\u00abL\u2019organisation apporte un soutien ind\u00e9fectible \u00e0 notre important travail sur l\u2019antibior\u00e9sistance, ce qui fournit une base solide \u00e0 notre \u00e9quipe. Nous avons ainsi la possibilit\u00e9 de travailler \u00e0 changer la donne.\u00bb<\/h2>\n \n

Man-Wah Tan (Vice-pr\u00e9sident et Senior Fellow au Centre de recherche et d\u00e9veloppement Genentech (Genentech Research and Early Development, gRED))<\/p>\n \n

<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n \n\n\n\n\n

Chaque unit\u00e9 de recherche utilise une approche l\u00e9g\u00e8rement diff\u00e9rente dans le d\u00e9veloppement de nouveaux antibiotiques. Le pRED coop\u00e8re avec des universitaires pour recruter de jeunes scientifiques pour ce domaine et \u00abtout passer au peigne fin\u00bb pour trouver de nouvelles structures chimiques pour ces m\u00e9dicaments, d\u00e9crit Michael Lobritz. On teste ces mol\u00e9cules par des m\u00e9thodes de criblage aussi bien traditionnelles que nouvelles de mani\u00e8re \u00e0 identifier les candidates les plus prometteuses. Cela g\u00e9n\u00e8re une grande richesse d\u2019informations et une \u00e9quipe d\u2019expert-e-s de diff\u00e9rents domaines qui se consacrent au d\u00e9veloppement d\u2019antibiotiques aident \u00e0 structurer ces mol\u00e9cules pour un maximum d\u2019efficacit\u00e9 et de s\u00e9curit\u00e9.<\/p>\n\n\n\n

Entre-temps, le gRED combine des approches de laboratoire traditionnelles avec une nouvelle strat\u00e9gie: il s\u2019agit d\u2019utiliser l\u2019IA pour d\u00e9couvrir de nouvelles mol\u00e9cules auxquelles m\u00eame des chimistes exp\u00e9riment\u00e9-e-s n\u2019auraient peut-\u00eatre pas pens\u00e9 ou qui n\u2019existent pas dans la nature. \u00abNous veillons \u00e0 des approches ind\u00e9pendantes du probl\u00e8me, de mani\u00e8re \u00e0 \u00e9viter le risque de suivre le troupeau\u00bb, souligne Man-Wah Tan<\/a>. Mais il insiste aussi sur le fait que la coop\u00e9ration entre le pRED et le gRED est cruciale: \u00abNous partageons l\u2019exp\u00e9rience et les r\u00e9actifs entre le pRED et le gRED et cette plateforme est fertile pour les performances des deux groupes. Les m\u00e9thodes de criblage du pRED produisent des donn\u00e9es de haute qualit\u00e9 que nous pouvons utiliser dans notre mod\u00e8le d\u2019IA. C\u2019est ce \u2018nous\u2019 qui fait notre sp\u00e9cificit\u00e9.\u00bb<\/p>\n\n\n\n

Michael Lobritz confirme: \u00abNous pouvons exploiter ces synergies et la strat\u00e9gie du \u2018laboratoire en boucle\u2019 du gRED<\/a>, qui utilise l\u2019IA, permet d\u2019acc\u00e9der \u00e0 des espaces chimiques qui vont bien au-del\u00e0 de nos biblioth\u00e8ques. Tout ceci combin\u00e9 et gr\u00e2ce aux investissements \u00e0 long terme de Roche, nous avons une extraordinaire quantit\u00e9 de donn\u00e9es toxicologiques, chimiques et sur la s\u00e9curit\u00e9 qui nous sert de base\u00bb, ajoute-t-il. Man-Wah Tan souligne \u00e9galement l\u2019engagement de Roche dans le domaine du diagnostic des maladies infectieuses, avec le d\u00e9veloppement de diagnostics pour les infections microbiennes les plus courantes, comme par exemple \u00e0 Acinetobacter. \u00abCe sont des travaux difficiles et l\u2019innovation n\u2019avance pas rapidement\u00bb, r\u00e9sume Michael Lobritz. \u00abMais nous avons un portefeuille jeune et, fondamentalement, l\u2019engagement et le soutien de Roche sont un moteur puissant de notre succ\u00e8s.\u00bb<\/p>\n\n\n\n

Cliquez ici pour acc\u00e9der \u00e0 la partie 1 de la s\u00e9rie d’articles<\/a><\/p>\n\n\n\n

Cliquez ici pour acc\u00e9der \u00e0 la partie 2 de la s\u00e9rie d’articles<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Organis\u00e9e \u00e0 l\u2019\u00e9chelon mondial, l\u2019\u00abAMR Awareness Week\u00bb a pour but de sensibiliser \u00e0 l\u2019antibior\u00e9sistance et de faire progresser les approches de solutions. Cette s\u00e9rie de blogs propose un aper\u00e7u du r\u00f4le de l\u2019industrie pharmaceutique dans la lutte contre l\u2019antibior\u00e9sistance. La troisi\u00e8me et derni\u00e8re partie de ce blog porte sur les succ\u00e8s de la lutte contre […]<\/p>\n","protected":false},"author":1,"featured_media":9150,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[115,120],"class_list":["post-11938","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-recherche-fr","tag-innovation-fr"],"acf":[],"yoast_head":"\nAMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance\" \/>\n<meta property=\"og:description\" content=\"Organis\u00e9e \u00e0 l\u2019\u00e9chelon mondial, l\u2019\u00abAMR Awareness Week\u00bb a pour but de sensibiliser \u00e0 l\u2019antibior\u00e9sistance et de faire progresser les approches de solutions. Cette s\u00e9rie de blogs propose un aper\u00e7u du r\u00f4le de l\u2019industrie pharmaceutique dans la lutte contre l\u2019antibior\u00e9sistance. La troisi\u00e8me et derni\u00e8re partie de ce blog porte sur les succ\u00e8s de la lutte contre […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-21T09:55:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-12T14:14:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2021\/11\/Blog-thumbnail-1200x1200.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"AMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance\",\"datePublished\":\"2025-11-21T09:55:56+00:00\",\"dateModified\":\"2026-03-12T14:14:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/\"},\"wordCount\":990,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2021\/11\/Blog-thumbnail-scaled.png\",\"keywords\":[\"Recherche\",\"Innovation\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/\",\"name\":\"AMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2021\/11\/Blog-thumbnail-scaled.png\",\"datePublished\":\"2025-11-21T09:55:56+00:00\",\"dateModified\":\"2026-03-12T14:14:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2021\/11\/Blog-thumbnail-scaled.png\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2021\/11\/Blog-thumbnail-scaled.png\",\"width\":2560,\"height\":2560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/","og_locale":"fr_FR","og_type":"article","og_title":"AMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance","og_description":"Organis\u00e9e \u00e0 l\u2019\u00e9chelon mondial, l\u2019\u00abAMR Awareness Week\u00bb a pour but de sensibiliser \u00e0 l\u2019antibior\u00e9sistance et de faire progresser les approches de solutions. Cette s\u00e9rie de blogs propose un aper\u00e7u du r\u00f4le de l\u2019industrie pharmaceutique dans la lutte contre l\u2019antibior\u00e9sistance. La troisi\u00e8me et derni\u00e8re partie de ce blog porte sur les succ\u00e8s de la lutte contre […]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/","og_site_name":"Interpharma","article_published_time":"2025-11-21T09:55:56+00:00","article_modified_time":"2026-03-12T14:14:09+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2021\/11\/Blog-thumbnail-1200x1200.png","type":"image\/png"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"AMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance","datePublished":"2025-11-21T09:55:56+00:00","dateModified":"2026-03-12T14:14:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/"},"wordCount":990,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2021\/11\/Blog-thumbnail-scaled.png","keywords":["Recherche","Innovation"],"inLanguage":"fr-FR","copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/","name":"AMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2021\/11\/Blog-thumbnail-scaled.png","datePublished":"2025-11-21T09:55:56+00:00","dateModified":"2026-03-12T14:14:09+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2021\/11\/Blog-thumbnail-scaled.png","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2021\/11\/Blog-thumbnail-scaled.png","width":2560,"height":2560},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/amr-awareness-week-2025-partie-3-succes-dans-la-lutte-contre-lantibioresistance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"AMR Awareness Week 2025, partie 3: Succ\u00e8s dans la lutte contre l\u2019antibior\u00e9sistance"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/11938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=11938"}],"version-history":[{"count":4,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/11938\/revisions"}],"predecessor-version":[{"id":15662,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/11938\/revisions\/15662"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/9150"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=11938"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=11938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}